Breaking News Instant updates and real-time market news.

A

Agilent

$65.67

0.72 (1.11%)

, AZN

AstraZeneca

$38.66

-0.11 (-0.28%)

04:55
08/23/18
08/23
04:55
08/23/18
04:55

American Chemical Society to hold a meeting

2018 Fall National Meeting & Exposition will be held in Boston on August 19-23.

A

Agilent

$65.67

0.72 (1.11%)

AZN

AstraZeneca

$38.66

-0.11 (-0.28%)

BASFY

BASF

$0.00

(0.00%)

BMY

Bristol-Myers

$60.56

0.5 (0.83%)

BRKR

Bruker

$34.67

0.2 (0.58%)

CTAS

Cintas

$212.44

0.46 (0.22%)

FTI

TechnipFMC

$29.92

0.65 (2.22%)

LLY

Eli Lilly

$105.03

-0.04 (-0.04%)

GSK

GlaxoSmithKline

$41.54

0.025 (0.06%)

HP

Helmerich & Payne

$65.44

1.05 (1.63%)

LNKD

Acquired by MSFT

$0.00

(0.00%)

MON

Bought by BAYRY

$0.00

(0.00%)

MTD

Mettler-Toledo

$566.52

2.445 (0.43%)

MRK

Merck

$69.05

-0.12 (-0.17%)

OMER

Omeros

$22.57

0.17 (0.76%)

PKI

PerkinElmer

$86.85

0.64 (0.74%)

PFE

Pfizer

$42.08

-0.08 (-0.19%)

TMO

Thermo Fisher

$234.27

2.83 (1.22%)

BAYRY

Bayer

$0.00

(0.00%)

  • 23

    Aug

  • 23

    Aug

  • 24

    Aug

  • 25

    Aug

  • 27

    Aug

  • 27

    Aug

  • 05

    Sep

  • 05

    Sep

  • 10

    Sep

  • 11

    Sep

  • 12

    Sep

  • 26

    Sep

  • 03

    Oct

  • 17

    Oct

  • 22

    Oct

  • 23

    Oct

  • 29

    Oct

  • 16

    Feb

A Agilent
$65.67

0.72 (1.11%)

05/15/18
COWN
05/15/18
UPGRADE
COWN
Outperform
Agilent upgraded to Outperform from Market Perform at Cowen
06/08/18
BARD
06/08/18
NO CHANGE
Target $77
BARD
Outperform
Agilent recent weakness a buying opportunity, says Baird
Baird analyst Catherine Ramsey Schulte attended Agilent's analyst day and said her positive outlook on the company remains unchanged. She continues to expect strong core growth and margin expansion to help drive above market performance over the next several years. Schulte said she would use recent weakness as a buying opportunity and reiterated her Outperform rating and $77 price target on Agilent shares.
05/15/18
JEFF
05/15/18
NO CHANGE
Target $80
JEFF
Buy
Agilent pullback a buying opportunity, says Jefferies
Jefferies analyst Brandon Couillard recommends using the post-earnings pullback in shares of Agilent Technologies as a buying opportunity. Guidance was maintained, despite dilution from Lasergen, and does not yet capture accretion from the pending AATI deal, Couillard tells investors in a research note. He sees no reason to alter his positive thesis and keeps a Buy rating on Agilent with a slightly reduced price target of $80.
06/28/18
JPMS
06/28/18
DOWNGRADE
Target $105
JPMS
Underweight
JPMorgan downgrades Varian to Underweight following period of restriction
JPMorgan analyst Tycho Peterson downgraded Varian Medical Systems (VAR) to Underweight from Neutral following a period of restriction. Persistent order growth volatility, a "sluggish" end market and in the near-term and risk from the U.S.-China trade war weigh on the analyst's longer-term outlook for the stock. Varian has a dominant franchise but a mature industry and premium valuation are hard to overlook, Peterson tells investors in a research note. The analyst sees better risk/rewards in other parts of his coverage universe, including tool names Agilent (A), Danaher (DHR) and Thermo Fisher (TMO).
AZN AstraZeneca
$38.66

-0.11 (-0.28%)

08/16/18
08/16/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. AstraZeneca (AZN) downgraded to Hold from Buy at Jefferies with analyst Ian Hilliker citing valuation following the stock's outperformance since he upgraded it in March. 2. Cemex (CX) downgraded to Hold from Buy at HSBC with analyst Eduardo Altamirano saying Cemex's deleveraging remains intact, but the pace at which debt is converted to equity is slowing down due to weaker than expected pricing and volumes in most regions, combined with higher input costs. 3. Cenovus Energy (CVE) downgraded to Hold from Buy at Canaccord with analyst Dennis Fong saying cash flow valuation is in line versus the large-cap group, which he thinks is appropriate given the company's above-average heavy oil exposure, moderated production growth profile, and higher leverage. 4. Nanometrics (NANO) downgraded to Neutral from Buy at DA Davidson with analyst Thomas Diffely saying that after outperforming its peer group over the past few years, the stock now trades at a 40% premium to its peers. 5. Coty (COTY) downgraded to Underperform from Buy at BofA/Merrill with analyst Olivia Tong citing inconsistent execution and increasing disruption across the mass beauty segment. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
08/16/18
08/16/18
DOWNGRADE

Hold
AstraZeneca downgraded to Hold following outperformance at Jefferies
As previously reported, Jefferies analyst Ian Hilliker downgraded AstraZeneca (AZN) to Hold from Buy citing valuation following the stock's outperformance since he upgraded it in March. Hilliker has raised his price target on AstraZeneca to 6,200p, but notes that this only leaves about 8% of further upside. Following results for the Q2 period, Hilliker said Novartis (NVS) remains his top European Pharmaceuticals pick, followed by Roche (RHHBY) and GlaxoSmithKline (GSK) in third place.
08/16/18
JEFF
08/16/18
DOWNGRADE
JEFF
Hold
AstraZeneca downgraded to Hold from Buy at Jefferies
08/08/18
HCWC
08/08/18
NO CHANGE
Target $43
HCWC
Buy
Insmed likely to be acquired after positive panel vote, says H.C. Wainwright
H.C. Wainwright analyst Andrew Fein raised his price target for Insmed (INSM) to $43 from $35 following yesterday's 12-2 FDA panel vote in favor of ALIS in refractory nontuberculous mycobacterial patients. Insmed is now likely to be acquired as ALIS "fits well within the pipeline of a number of larger companies," Fein tells investors in a research note. He expects the company's Q3 conference call "may well be its last." The analyst sees AstraZeneca (AZN), Gilead Sciences (GILD) and Vertex Pharmaceuticals (VRTX) as potential acquirers of Insmed. He reiterates a Buy rating on Insmed.
BASFY BASF
$0.00

(0.00%)

01/08/18
JPMS
01/08/18
DOWNGRADE
JPMS
Neutral
BASF downgraded to Neutral from Overweight at JPMorgan
JPMorgan analyst Chetan Udeshi downgraded BASF to Neutral citing a more defensive stance on European Chemicals. The analyst believes the cycle could be peaking, which he thinks warrants a more cautious stance. He lowered his price target for BASF shares to EUR 95 from EUR 105.
11/22/17
BREN
11/22/17
UPGRADE
BREN
Buy
BASF upgraded to Buy from Hold at Berenberg
Berenberg analyst Sebastian Bray upgraded BASF to Buy.
12/07/17
UBSW
12/07/17
DOWNGRADE
UBSW
Neutral
BASF downgraded to Neutral from Buy at UBS
UBS analyst Andrew Gregory Stott downgraded BASF to Neutral with a price target of EUR 99 citing valuation and building macro headwinds.
BMY Bristol-Myers
$60.56

0.5 (0.83%)

08/08/18
08/08/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Dean Foods (DF) upgraded to Hold from Sell at Deutsche Bank. 2. Plantronics (PLT) upgraded to Buy from Neutral at Sidoti with the firm citing attractive valuation. 3. CarGurus (CARG) upgraded to Outperform from Market Perform at JMP Securities and to Outperform from Sector Perform at RBC Capital. 4. Bristol-Myers (BMY) upgraded to Neutral from Underweight at Atlantic Equities. 5. Floor & Decor (FND) upgraded to Buy from Hold at Loop Capital with analyst Anthony Chukumba saying the company continues to post the "best relative performance in the flooring retailing industry." This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
07/11/18
WELS
07/11/18
NO CHANGE
WELS
Drug stocks may not react favorably to Pfizer price rollback, Trump tweets, says Wells Fargo
Wells Fargo analyst David Maris notes that there was widespread media coverage of drug price increases taken recently by several large cap drug companies, with President Trump criticizing Pfizer (PFE) for taking these price increases. On Tuesday, Pfizer confirmed it was rolling back its July drug price increases following a conversation with President Trump, he adds. Maris believes that drug stocks will not react favorably to this news, given the chilling effect this will likely have on others looking to take price increases. Nonetheless, the analyst points out that the price increases taken in July are only a small number of increases taken over the past year or several years, so the impact of the rollback to the healthcare system is insignificant in the big picture. Other publicly traded companies in the space include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Roche (RHHBY) and Sanofi (SNY).
07/23/18
BMOC
07/23/18
NO CHANGE
Target $51
BMOC
Market Perform
Bristol-Myers price target raised to $51 from $47 at BMO Capital
BMO Capital analyst Alex Arfaei raised his price target on Bristol-Myers to $51, saying the company's Opdivo+Yervoil will likely top consensus thanks to "good growth" in the U.S. markets and that the Eliquis RX trends were likely "remarkably strong". The analyst further states that the stock price should respond positively to the likely earnings beat and may lead to some "takeout speculation", particularly if the sustainability of its immuno-oncology franchse is made clearer. Arfaei also keeps his Market Perform rating, adding that at current price levels, risk-reward is not favorable for the stock.
08/08/18
ATLE
08/08/18
UPGRADE
ATLE
Neutral
Bristol-Myers upgraded to Neutral from Underweight at Atlantic Equities
BRKR Bruker
$34.67

0.2 (0.58%)

01/05/18
BTIG
01/05/18
INITIATION
Target $42
BTIG
Buy
Bruker initiated with a Buy at BTIG
BTIG analyst Sung Ji Nam started Bruker with a Buy rating and $42 price target. The analyst believes the company is well positioned to reaccelerate its sales growth over the next 12 to 24 months amid improving end markets.
01/03/18
EVER
01/03/18
INITIATION
Target $36
EVER
In Line
Bruker initiated with an In Line at Evercore ISI
Evercore ISI analyst Ross Muken started Bruker with an In Line rating and $36 price target.
11/03/17
BOFA
11/03/17
UPGRADE
Target $34
BOFA
Neutral
Bruker upgraded to Neutral from Underperform at BofA/Merrill
BofA/Merrill analyst Derik de Bruin upgraded Bruker to Neutral and raised its price target to $34 from $27 following the better than expected Q3 report and guidance. The analyst said key European academic and global industrial markets are rebounding and thinks recent organic growth momentum will continue into 2018.
11/03/17
JPMS
11/03/17
UPGRADE
Target $28
JPMS
Neutral
Bruker upgraded to Neutral from Underweight at JPMorgan
JPMorgan analyst Tycho Peterson upgraded Bruker to Neutral and raised his price target for the shares to $28 from $23. The analyst sees an improving growth outlook following another beat and raise quarter in Q3.
CTAS Cintas
$212.44

0.46 (0.22%)

12/22/17
BARD
12/22/17
NO CHANGE
Target $185
BARD
Outperform
Cintas price target raised to $185 from $165 at Baird
Baird analyst Andrew Wittman raised his price target on Cintas to $185 from $165 following another solid beat. The analyst noted solid organic gains and gross margins, the on-track integration of G&K Services and solid long-term potential. He sees solid fundamentals and the company's competitive moat widening. Wittman reiterated his Outperform rating on Cintas shares.
08/10/18
FBCO
08/10/18
INITIATION
Target $205
FBCO
Neutral
Cintas initiated with a Neutral at Credit Suisse
Credit Suisse analyst Kevin McVeigh initiated shares of Cintas with a Neutral rating and $205 price target, telling investors in a research note that while Cintas is "the clear leader" in uniforms with impressive MSD-HSD growth, this is "more than reflected" in the stock price. Additionally, McVeigh says that given the current small business hiring environment that is moderating on tight supply and his late-cycle view, he does not see an attractive risk/reward at current levels.
01/25/18
BARD
01/25/18
NO CHANGE
Target $185
BARD
Outperform
Cintas long-term opportunity remains significant, says Baird
Baird analyst Andrew Wittmann believes Cintas' long-term opportunity remains significant with plenty of small items likely adding up to big share gains and strong financial returns over time. He believes the company's executive and operations-level management remain underappreciated and their execution will further separate them from the competition. Wittmann reiterated his Outperform rating and $185 price target on Cintas shares.
03/27/18
GSCO
03/27/18
INITIATION
Target $210
GSCO
Conviction Buy
Cintas initiated with a Conviction Buy at Goldman Sachs
Goldman Sachs analyst George Tong started Cintas with a Conviction Buy rating and $210 price target. The analyst rolled out coverage on the Americas Business Services sector with an Attractive rating.
FTI TechnipFMC
$29.92

0.65 (2.22%)

08/16/18
08/16/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Lululemon (LULU) upgraded to Buy from Hold at Argus with analyst John Staszak citing the company's Q1 earnings beat and expectations of improved comps in Q2, along with its "substantial" growth opportunities to expand its brand overseas and particularly in China. 2. Kimberly-Clark (KMB) upgraded to Neutral from Underweight at JPMorgan analyst Andrea Teixeira saying while it remains to be seen if the company's recently announced price increases will "actually hold" given the intensely competitive U.S. market, she believes investors will give Kimberly-Clark shares the benefit of the doubt. 3. Embraer (ERJ) upgraded to Overweight from Equal Weight at Morgan Stanley with analyst Josh Milberg sayng the 29% selloff in the stock since its strategic partnership with Boeing (BA) was announced in early July has made the risk-reward attractive. 4. TechnipFMC (FTI) upgraded to Buy from Hold at Jefferies with analyst Mark Wilson saying same-year "book & turn" work and recent awards have lead him to raise his revenue forecasts through 2020. 5. Avalara (AVLR) upgraded to Buy from Neutral at Goldman Sachs with analyst Jesse Hulsing was saying the company has "significantly underperformed" his coverage over the past month following a post-IPO overshoot and created an opportunity for investors. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
07/17/18
FBCO
07/17/18
INITIATION
Target $38.28
FBCO
Outperform
TechnipFMC assumed with an Outperform at Credit Suisse
Credit Suisse analyst Jim Wicklund assumed coverage of TechnipFMC with an Outperform rating and $38.28 price target.
08/16/18
JEFF
08/16/18
UPGRADE
JEFF
Buy
TechnipFMC upgraded to Buy from Hold at Jefferies
08/16/18
08/16/18
UPGRADE
Target $37

Buy
TechnipFMC upgraded to Buy on better winning percentage at Jefferies
As previously reported, Jefferies analyst Mark Wilson upgraded TechnipFMC to Buy from Hold as same-year "book & turn" work and recent awards have lead him to raise his revenue forecasts through 2020. He believes that the company is winning a greater proportion of available business and also that the overall industry pipeline remains robust, Wilson tells investors. He raised his price target on TechnipFMC shares to $37 from $30.
LLY Eli Lilly
$105.03

-0.04 (-0.04%)

08/07/18
STFL
08/07/18
INITIATION
Target $30
STFL
Buy
Alder Biopharmaceuticals initiated with a Buy at Stifel
Stifel analyst Paul Matteis initiated coverage of Alder BioPharmaceuticals with a Buy rating and $30 price target, calling it an attractive, differentiated "pure play" within the migraine antiCGRP prevention market. While Matteis acknowledges it "won't be easy" for Alder to compete with Amgen (AMGN), Novartis (NVS), Eli Lilly (LLY) and Teva (TEVA), he believes the unique profile of eptinezumab remains underappreciated and may allow it to capture meaningful, above consensus share of a large, emerging drug category.
07/25/18
07/25/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Spotify (SPOT) downgraded to Hold from Buy at Pivotal Research with analyst Jeffrey Wlodarczak citing valuation. 2. Eli Lilly (LLY) downgraded to Hold from Buy at Berenberg with analyst Laura Sutcliffe saying the company reported "very good" Q2 results and its sales growth is built on the "solid proposition" of Trulicity, but the company is in the process of re-stocking its late-stage pipeline both internally and via deals. 3. Walmart (WMT) downgraded to Hold from Accumulate at Gordon Haskett with analyst Chuck Grom saying he thinks there are few near-term catalysts on the horizon and the margin outlook is not as transparent following a period of improvement and stabilization, and expects shares to be range bound for the balance of the year. 4. Hormel Foods (HRL) downgraded to Underperform from Neutral at Mizuho with analyst Jeremy Scott saying "volatile and retreating" pork margins bring rising risks to Hormel's earnings. 5. BJ's Wholesale (BJ) downgraded to Accumulate from Buy at Gordon Haskett with analyst Chuck Grom citing share strength following the IPO. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
07/25/18
BMOC
07/25/18
NO CHANGE
Target $90
BMOC
Market Perform
Eli Lilly price target raised to $90 from $80 at BMO Capital
BMO Capital analyst Alex Arfaei raised his price target on Eli Lilly to $90, saying the company is doing an "excellent" job in managing its mature franchises and should finish 2018 at the top end of its guidance. The analyst also believes that the company can achieve its 2015-20 annual revenue growth target of 5% or more. Arfaeil keeps his Market Perform rating however, noting that its valuation reflects the opportunities around Tanezumab, migraine and Alzheimer's franchises while also pointing to the "underappreciated" risks around its insulins franchise.
07/25/18
07/25/18
DOWNGRADE
Target $99

Hold
Eli Lilly downgraded to Hold on valuation at Berenberg
As previously reported, Berenberg analyst Laura Sutcliffe downgraded Eli Lilly to Hold from Buy, stating that the company reported "very good" Q2 results and its sales growth is built on the "solid proposition" of Trulicity, but the company is in the process of re-stocking its late-stage pipeline both internally and via deals. While she thinks Lilly's premium to peers is deserved, Sutcliffe also sees the stock at a "reasonably full valuation" at current levels, she tells investors. She trimmed her price target on Lilly shares to $99 from $100.
GSK GlaxoSmithKline
$41.54

0.025 (0.06%)

07/25/18
WELS
07/25/18
NO CHANGE
WELS
Market Perform
Even minor delays can hurt Mylan's generic Advair opportunity, says Wells Fargo
After GlaxoSmithKline (GSK) reported U.S. Advair sales declined 43% at constant currency in Q2, Wells Fargo analyst David Maris commented on the read-through to the generic Advair opportunity being pursued by Mylan (MYL). Given the substantial declines branded Advair faces, he said that "even minor delays" can continue to hurt the potential generic opportunity, adding that he has not seen or been notified of any updates from Mylan on Advair since the company was notified in early June that the FDA planned to issue an official Complete Response Letter related to its application. Maris keeps a Market Perform rating on Mylan shares.
08/15/18
RBCM
08/15/18
NO CHANGE
RBCM
Outperform
RBC says Gilead weakness on CMO leaving, Glaxo data a buying opportunity
RBC Capital analyst Brian Abrahams believes Gilead's (GILD) weakness is potentially due to data from GlaxoSmithKline's (GSK) ATLAS trial and last night's announcement of the departure of its CMO. However, he does not see either as a major fundamental concern and would use the weakness in Gilead shares as a buying opportunity. Feedback he has received from doctors is that injectables like Glaxo's could be used in a select number of patients, but he does not see a major impact on Gilead's HIV franchise near- or long-term from this product, Abrahams said. On the CMO departure, the analyst said that the company clarified that this is "completely unrelated" to the recently-announced CEO transition, so he does not see this reflecting any major structural issue. Abrahams keeps an Outperform rating on Gilead shares, which are down over 3% to $74.82 in afternoon trading.
HP Helmerich & Payne
$65.44

1.05 (1.63%)

06/19/18
JEFF
06/19/18
UPGRADE
Target $80
JEFF
Buy
Helmerich & Payne upgraded to Buy from Hold at Jefferies
Jefferies analyst Brad Handler upgraded Helmerich & Payne to Buy and raised his price target for the shares to $80 from $72. The stock's 13% pullback over the past month is unwarranted, Handler tells investors in a research note. The analyst expects any Permian fall-off to "be shallow and limited" to the second half of 2018. Further, he believes U.S. land drilling fundamentals remain strong. Helmerich retains "best-in-class exposure to a super-spec rig market" that should allow for strong free cash flow inflection through the next 24 months, the analyst contends.
06/19/18
06/19/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Verizon (VZ) upgraded to Buy from Hold at Deutsche Bank with analyst Matthew Niknam saying the company's fundamentals are inflecting but the shares have remained range-bound. 2. Intuit (INTU) upgraded to Buy from Hold at Stifel with analyst Brad Reback saying he believes its two primary business divisions each have improving competitive dynamics and multiple secular growth drivers. 3. First Solar (FSLR) upgraded to Neutral from Underperform at Credit Suisse with analyst Michael Weinstein saying the recent pull back captures potential downside risk from U.S. tariff withdrawal. 4. Helmerich & Payne (HP) upgraded to Buy from Hold at Jefferies with analyst Brad Handler saying the stock's 13% pullback over the past month is unwarranted. 5. Accenture (ACN) upgraded to Positive from Neutral at Susquehanna with analyst James Friedman saying he is incrementally more bullish that an ERP modernization cycle is starting. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
07/30/18
07/30/18
UPGRADE
Target $85

Overweight
Stephens says Helmerich & Payne 'best-in-class' several ways, ups to Overweight
As previously reported, Stephens analyst Tommy Moll upgraded Helmerich & Payne to Overweight from Equal Weight, stating that it has the "best-in-class" drilling fleet, "cleanest" balance sheet and highest dividend among its peers and he expects continued earnings momentum given the company's discipline. With the stock down almost 20% since May, he believes the recent divergence in fundamentals and stock performance has created a buying opportunity, Moll tells investors. He raised his price target on Helmerich & Payne shares to $85 from $75.
07/30/18
SPHN
07/30/18
UPGRADE
SPHN
Overweight
Helmerich & Payne upgraded to Overweight from Equal Weight at Stephens
LNKD Acquired by MSFT
$0.00

(0.00%)

MON Bought by BAYRY
$0.00

(0.00%)

07/06/18
BERN
07/06/18
NO CHANGE
BERN
Brazil ruling a 'big negative' for Monsanto, says Bernstein
Bernstein analyst Jonas Oxgaard noted the news that a Brazilian judge has ordered local units of Monsanto (MON) in the state of Mato Grosso to deposit royalties for Intacta RR2 Pro into an escrow account, which he calls a "big negative" for Monsanto as he estimates it keeps about $200M in royalties from the company and Bayer (BAYRY) in the next season. The news is also a "minor negative" for DowDuPont (DWDP), Oxgaard tells investors.
04/16/18
ARGS
04/16/18
DOWNGRADE
ARGS
Sell
Monsanto downgraded to Sell from Buy at Argus
Argus analyst Bill Selesky issued a double-notch downgrade on Monsanto (MON) to Sell from Buy after the U.S. Justice Department approved its acquisition by Bayer (BAYRY) last week. The analyst says the deal is expected to be further approved by Canadian and Mexican regulators and completed by the end of Q2. As part of the approval, the analyst points to the companies' pledge to sell additional assets even as Monsanto stock trades just below Bayer's acquisition price of $128 per share.
04/10/18
04/10/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Monsanto (MON) downgraded to Market Perform from Outperform at BMO Capital with analyst Joel Jackson citing the rising likelihood of the acquisition by Bayer (BAYRY) after yesterday's reports of approval of the merger by the U.S. Department of Justice. 2. Hershey (HSY) downgraded to Sell from Neutral at UBS with analyst Steven Strycula saying Hershey's portfolio is over-exposed to slowing category consumption, intensifying competition, and rising cocoa prices. 3. Cullen/Frost (CFR) downgraded to Underperform from Market Perform at Raymond James. 4. vTv Therapeutics (VTVT) downgraded to Hold from Buy at Stifel, to Neutral from Buy at Seaport Global, Piper Jaffray, and Roth Capital, as well as to Market Perform from Outperform at Northland. 5. Radian Group (RDN) downgraded to Sector Perform from Outperform at RBC Capital with analyst Mark Dwelle citing the latest reduction in borrower-paid premium rates at MGIC Investment (MTG) and saying he believes sentiment in the space will be negatively impacted. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
04/10/18
BMOC
04/10/18
DOWNGRADE
Target $128
BMOC
Market Perform
Monsanto downgraded to Market Perform at BMO Capital on Bayer deal prospects
As reported earlier, BMO Capital analyst Joel Jackson downgraded Monsanto (MON) to Market Perform from Outperform while keeping his $128 price target. Jackson cites the rising likelihood of the acquisition by Bayer (BAYRY) after yesterday's reports of approval of the merger by the U.S. Department of Justice. The analyst notes that since the stock price is now so close to Bayer's takeout price, the isn't "sufficient spread" to support a more bullish rating. In the event of a breakdown of the deal, Jackson sees downside support for the stock around $110 per share.
MTD Mettler-Toledo
$566.52

2.445 (0.43%)

04/09/18
GSCO
04/09/18
UPGRADE
Target $77
GSCO
Buy
Goldman upgrades Agilent to Buy ahead of Q1 earnings season
Goldman Sachs analyst Patrick Donnelly upgraded Agilent Technologies (A) to Buy from Neutral and raised his price target for the shares to $77 from $73. Heading into the Q1 earnings season, the analyst sees an attractive fundamental backdrop across Tools. He believes, however, that the favorable backdrop is well understood by investors with valuations that "remain well-above 10-year highs." The analyst prefers the "idiosyncratic drivers of growth" for Agilent in the out years and views the stock's relative valuation as attractive. He coupled the upgrade with a downgrade of Mettler-Toledo (MTD) to Neutral.
04/09/18
GSCO
04/09/18
DOWNGRADE
Target $600
GSCO
Neutral
Goldman downgrades Mettler-Toledo to Neutral ahead of Q1 earnings
Goldman Sachs analyst Patrick Donnelly downgraded Mettler-Toledo (MTD) to Neutral from Buy and cut his price target for the shares to $600 from $725. Heading into the Q1 earnings season, the analyst sees an attractive fundamental backdrop across Tools. He believes, however, that the favorable backdrop is well understood by investors with valuations that "remain well-above 10-year highs." The analyst is more cautious on the outlook for sales upside at Mettler given his view of a likely moderation of growth in China after a year of catch-up investment in the region. Donnelly also highlights "tough comps" in Labs and Product inspection. He coupled the downgrade with an upgrade of Agilent Technologies (A) to Buy.
04/09/18
04/09/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Westlake Chemical (WLK) downgraded to Neutral from Overweight at JPMorgan with analyst Jeffrey Zekauskas citing valuation. 2. Mettler-Toledo (MTD) downgraded to Neutral from Buy at Goldman Sachs with analyst Patrick Donnelly saying he sees an attractive fundamental backdrop across Tools but is more cautious on the outlook for sales upside at Mettler given his view of a likely moderation of growth in China after a year of catch-up investment in the region. Donnelly also highlights "tough comps" in Labs and Product inspection. 3. Franklin Resources (BEN) downgraded to Neutral from Buy at BofA/Merrill with analyst Michael Carrier saying Franklin's bottom half performance and continued outflows limits organic growth and multiple expansion. 4. NewLink Genetics (NLNK) downgraded to Neutral from Overweight at Cantor Fitzgerald and Baird as well as to Hold from Buy at Jefferies. 5. Incyte (INCY) downgraded to Hold from Buy at Gabelli with analyst Jing He citing the "surprising" failure of the Phase 3 ECHO-301 study in melanoma. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
05/01/18
CLVD
05/01/18
DOWNGRADE
CLVD
Neutral
Mettler-Toledo downgraded to Neutral on soft trends at Cleveland Research
Cleveland Research downgraded Mettler-Toledo to reflect softer Product Inspection trends, difficult comps, and expectations Q1 organic growth is more in-line with guidance.
MRK Merck
$69.05

-0.12 (-0.17%)

06/14/18
MSCO
06/14/18
NO CHANGE
Target $68
MSCO
Overweight
Merck Q2 estimates lowered below consensus at Morgan Stanley
Morgan Stanley analyst David Risinger cut his Q2 revenue estimate for Merck by 1% to $10.1B, which he notes is below the consensus view of $10.3B, and lowered his Q2 EPS estimate by 6% to 97c. This is below the consensus view of $1.03, which he argues "needs to come down." The two key drivers were lowering his estimates for Keytruda in the U.S. due to a more gradual ramp in first-line lung cancer patients and the negative impact of hedging, which he sees being similar to, but less pronounced, than in Q1. He lowered his full-year EPS view by only 1%, however, which puts it 2% below consensus. Risinger keeps an Overweight rating and $68 price target on Merck shares.
06/13/18
MSCO
06/13/18
NO CHANGE
MSCO
HHS 'smoke signals' worth noting for drugmakers, says Morgan Stanley
After HHS Secretary Alex Azar spoke at a two-hour Senate hearing, Morgan Stanley analyst David Risinger noted that Azar suggested that U.S. drug pricing needs to move to a system without rebates and said payments from drugmakers to PBMs should be eliminated. In listing four HHS actions that could hurt manufacturers, Risinger pointed out that Azar said he is interested in removing 100% cap on Medicaid rebates; he would like to adjust the Part D protected drug classes so that plans can extract rebates from manufacturers; HHS wants to require manufacturers to disclose drug list prices in TV ads; and HHS is focused on transitioning Part B to lower-priced private sector management. In summary, the analyst said that for drugmakers there was "no fire, but smoke signals worth noting." Publicly traded large-cap drugmakers include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).
06/28/18
WELS
06/28/18
NO CHANGE
WELS
Wells says Amazon deal, Walgreens results have negative read for drug pricing
After Amazon (AMZN) agreed to acquire online pharmacy PillPack, reportedly for $1B, Wells Fargo analyst David Maris noted that he has long stated that Amazon would enter the pharmacy business and warned about the risk to drug pricing in such a scenario. Maris also noted that Walgreens (WBA) reported its U.S. retail pharmacy comparable store sales fell 1.2% in Q3, adding that retailers tend to push drugmakers on price when they feel pressure and the read-through from its report may be negative for drug pricing. Publicly traded large-cap drugmakers include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).
OMER Omeros
$22.57

0.17 (0.76%)

03/23/18
HCWC
03/23/18
NO CHANGE
Target $34
HCWC
Buy
Omeros price target raised to $34 from $30 at H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju raised his price target for Omeros to $34 after Omidria pass-through reimbursement status was extended. The language in the spending bill provides the extension for a period of two years, Selvaraju tells investors in a research note. This is an "unexpected success" for Omeros, and should lead to a "significant rebound" in Omidria sales and resumption of growth in the franchise, Selvaraju writes. He reiterates a Buy rating on Omeros shares.
03/23/18
WEDB
03/23/18
DOWNGRADE
Target $19
WEDB
Neutral
Omeros downgraded to Neutral from Outperform at Wedbush
Wedbush analyst Liana Moussatos downgraded Omeros to Neutral and lowered her price target for the shares to $19 from $47. The analyst sees a "lack of clarity for the financial status" with disruption in Omidria sales and the company's inability to fund progress with its top potential value driver OMS721. Even with possible extension of Omidria pass-through reimbursement for two additional years starting in October 2018, sales are unlikely to fund the pipeline in 2018 and 2019, Moussatos tells investors in a research note. Omeros closed yesterday up 35%, or $4.11, to $15.75.
07/12/18
GHSC
07/12/18
INITIATION
Target $30
GHSC
Buy
Omeros initiated with a Buy at Seaport Global
Seaport Global analyst Corey Davis initiated Omeros with a Buy and $30 price target saying Omidria for cataract surgery regains pass-through starting October 1 following new legislation. Davis expects the company to quickly return to an annualized run-rate of $87M, and if it secures permanent reimbursement from CMS, likely $200M-$400M in peak sales.
03/22/18
MAXM
03/22/18
NO CHANGE
Target $25
MAXM
Buy
Omeros short-term reimbursement overhang removal 'great news,' says Maxim
Maxim analyst Jason McCarthy said Omeros resolution of of reimbursement "pass through" status removes an overhang. McCarthy expects Omidria to return to its previous trend of growing sales, and raised his estimates for 2018 to account for the news, while increasing his price target to $25 from $24 and reiterating a Buy rating on Omeros shares
PKI PerkinElmer
$86.85

0.64 (0.74%)

01/03/18
EVER
01/03/18
INITIATION
Target $77
EVER
In Line
PerkinElmer initiated with an In Line at Evercore ISI
Evercore ISI analyst Ross Muken initiated PerkinElmer with an In Line rating and $77 price target.
09/26/17
SBSH
09/26/17
NO CHANGE
Target $80
SBSH
Buy
PerkinElmer price target raised to $80 from $74 at Citi
Citi analyst Daniel Arias raised his price target for PerkinElmer shares to $80 after hosting meetings with management. The analyst left the meetings more optimistic that the company's ongoing portfolio evolution can drive a "material organic growth inflection." He maintains a Buy rating on PerkinElmer.
12/19/17
BOFA
12/19/17
UPGRADE
Target $78
BOFA
Neutral
PerkinElmer upgraded to Neutral from Underperform at BofA/Merrill
BofA/Merrill analyst Derik De Bruin upgraded PerkinElmer to Neutral and raised its price target to $78 from $70 ahead ot the pending $1.3B Eurolmmun acquisition. De Bruin said PerkinElmer has been pruning non-core and slower businesses and Eurolmmun is a key step in the portfolio transition with its solid and price competitive autoimmune testing business.
09/26/17
GSCO
09/26/17
INITIATION
Target $67
GSCO
Neutral
PerkinElmer assumed with a Neutral at Goldman Sachs
Goldman analyst Patrick Donnelly assumed coverage on PerkinElmer with a Neutral and $67 price target. The analyst expects below peer growth to continue and believes managements operating profit margin goal of 22% by 2020 is aggressive.
PFE Pfizer
$42.08

-0.08 (-0.19%)

08/22/18
BTIG
08/22/18
NO CHANGE
Target $95
BTIG
Buy
Exact Sciences price target raised to $95 from $70 at BTIG
BTIG analyst Sean Lavin raised his price target for Exact Sciences (EXAS) to $95 from $70 after the company announced a promotion agreement with Pfizer (PFE). The stock in midday trading is up 26%, or $13.11, to $63.16. The pact will meaningfully augment the number of sales reps selling Cologuard into primary care accounts and increase marketing spend, Lavin tells investors in a research note. The analyst views the news as a "clear plus" and believes it may make Cologuard a household name. It's now hard to imagine Cologuard not becoming standard of care, Lavin contends. He keeps a Buy rating on Exact Sciences.
08/16/18
HCWC
08/16/18
INITIATION
Target $6.5
HCWC
Buy
Aveo Pharmaceuticals initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Swayampakula Ramakanth initiated Aveo Pharmaceuticals (AVEO) with a Buy rating and $6.50 price target, citing the view that tivozanib offers potentially the "best-in-class" safety profile when compared to leading TKIs on the market, such as Pfizer's (PFE) Sutent and Bayer's (BAYRY) Nexavar. Ramakanth projects tivozanib to reach the U.S. market in 2020 and achieve risk-adjusted revenues of $651M by 2030.
08/21/18
DBAB
08/21/18
NO CHANGE
Target $45
DBAB
Buy
Pfizer price target raised to $45 ahead of pipeline event at Deutsche Bank
Deutsche Bank analyst Gregg Gilbert maintained a Buy rating on Pfizer and raised his price target to $45 from $42 ahead of data on the potential blockbuster drug tafamidis, which is "coming soon." Though Pfizer has already announced top-line results, the analyst tells investors in a research note that the full data set for tafamidis for the treatment of transthyretin cardiomyopathy, which will be presented on August 27, will help define the potential of the drug.
08/22/18
WBLR
08/22/18
NO CHANGE
WBLR
Outperform
Exact partnership with Pfizer 'adds serious firepower,' says William Blair
William Blair analyst Brian Weinstein says Exact Sciences' (EXAS) partnership with Pfizer (PFE) adds "serious firepower" to the uptake of Cologuard. The agreement begins in Q4 and provides for marketing support from Pfizer of $20M-$24M through 2021 and pays the company 50% of a calculated amount based on upside to revenue targets. These baseline revenues are above the current consensus for the next three years, Weinstein tells investors in a research note. While Exact is giving up some margin, it is getting a "massive infusion of firepower" to detail its Cologuard test to the general practitioner community and additional marketing dollars, the analyst adds. He keeps an Outperform rating on shares of Exact Sciences. The stock in premarket trading is up 22%, or $10.95, to $61.00.
TMO Thermo Fisher
$234.27

2.83 (1.22%)

02/01/18
LEER
02/01/18
NO CHANGE
Target $239
LEER
Outperform
Thermo Fisher price target raised to $239 from $200 at Leerink
Leerink analyst Puneet Souda raised his price target for Thermo Fisher to $239 from $200 on the back of now higher guide reflected in his estimates and valuation. The analyst reiterates an Outperform rating on the shares as he believes the company is a Life Science Tools leader with an unmatched scale, access to multiple growing end markets and now has a CDMO arm.
07/26/18
JPMS
07/26/18
NO CHANGE
Target $300
JPMS
Overweight
Thermo Fisher price target raised to $300 from $250 at JPMorgan
JPMorgan analyst Tycho Peterson raised his price target for Thermo Fisher to $300 saying the company yesterday reported "yet another strong quarter, delivering beats on both the top and bottom lines." The analyst continues to like the setup for the stock with "healthy end markets, updated guidance still leaving room for beat-and-raises throughout the year, and a clear path to organic revenue acceleration in 2019 and beyond." He reiterates an Overweight rating on Thermo Fisher.
07/26/18
LEER
07/26/18
NO CHANGE
Target $255
LEER
Outperform
Thermo Fisher price target raised to $255 from $239 at Leerink
Leerink analyst Puneet Souda raised his price target for Thermo Fisher to $255 from $239 as an "impressive" quarter sets stage for higher growth profile ahead. The analyst reiterates an Outperform rating on the shares.
BAYRY Bayer
$0.00

(0.00%)

08/21/18
08/21/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Symantec (SYMC) upgraded to Positive from Neutral at Susquehanna with analyst Anne Meisner saying that activist shareholder Starboard Value disclosing a 5.8% stake and nominating five directors to its board has introduced the potential for positive change. 2. Johnson Controls (JCI) upgraded to Buy from Hold at Argus with analyst John Eade citing the company's recent Q3 earnings beat along with the technical breakout in its stock price above the $38 resistance. 3. Discovery (DISCA) upgraded to Buy from Hold at Jefferies with analyst John Janedis saying he sees "several" opportunities that could increase Discovery's free cash flow, including stronger U.S. distribution growth, upside to realized synergies and the potential for a re-introduction of a repurchase earlier than anticipated. 4. Estee Lauder (EL) upgraded to Buy from Neutral at DA Davidson with analyst Linda Bolton Weiser saying the company's fundamentals are the "strongest seen in years," with a 21% rise in FY18 operating profit and an "achievable and potentially beatable" EPS growth outlook of 9%-11% for FY19. 5. Bayer (BAYRY) upgraded to Buy from Hold at Berenberg. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
08/15/18
JEFF
08/15/18
DOWNGRADE
JEFF
Hold
Bayer downgraded to Hold from Buy at Jefferies
08/21/18
BREN
08/21/18
UPGRADE
BREN
Buy
Bayer upgraded to Buy from Hold at Berenberg

TODAY'S FREE FLY STORIES

05:50
05/27/19
05/27
05:50
05/27/19
05:50
General news
FX Update: Conditions have been thin »

FX Update: Conditions…

03:30
05/27/19
05/27
03:30
05/27/19
03:30
General news
FX Action: USD-CAD has settled in the mid 1.3400s »

FX Action: USD-CAD has…

03:00
05/27/19
05/27
03:00
05/27/19
03:00
General news
FX Update: Risk-off positioning have unwound some more in the forex markets »

FX Update: Risk-off…

02:35
05/27/19
05/27
02:35
05/27/19
02:35
General news
Asian Market Wrap: »

Asian Market Wrap:…

TEVA

Teva

$10.86

-0.18 (-1.63%)

12:11
05/26/19
05/26
12:11
05/26/19
12:11
Hot Stocks
Teva reaches $85M agreement with State of Oklahoma »

Teva Pharmaceuticals USA…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ESLT

Elbit Systems

$141.85

1.33 (0.95%)

12:08
05/26/19
05/26
12:08
05/26/19
12:08
Hot Stocks
Elbit Systems awarded $127M contract to provide tactical radio system »

Elbit Systems announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    May

ADM

Archer Daniels

$39.17

-0.03 (-0.08%)

12:05
05/26/19
05/26
12:05
05/26/19
12:05
Hot Stocks
Archer Daniels expands recall of Baker's Corner All Purpose Flour 5lb bags »

ADM Milling is recalling…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

JCP

J.C. Penney

$0.93

0.022 (2.42%)

, DDS

Dillard's

$56.57

0.25 (0.44%)

13:29
05/25/19
05/25
13:29
05/25/19
13:29
Periodicals
Target stock triumphs in brutal week for retail, Barron's says »

Earnings season has been…

JCP

J.C. Penney

$0.93

0.022 (2.42%)

DDS

Dillard's

$56.57

0.25 (0.44%)

KSS

Kohl's

$51.11

-0.04 (-0.08%)

JWN

Nordstrom

$33.50

-0.31 (-0.92%)

M

Macy's

$21.00

-0.27 (-1.27%)

TGT

Target

$81.57

2.17 (2.73%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Jun

JPM

JPMorgan

$109.78

1.14 (1.05%)

, AKZOY

AkzoNobel

$0.00

(0.00%)

13:24
05/25/19
05/25
13:24
05/25/19
13:24
Periodicals
Microsoft, JPMorgan among dividend champions, Barron's says »

Among the companies that…

JPM

JPMorgan

$109.78

1.14 (1.05%)

AKZOY

AkzoNobel

$0.00

(0.00%)

XOM

Exxon Mobil

$74.12

0.33 (0.45%)

MSFT

Microsoft

$126.23

0.04 (0.03%)

CMWAY

Commonwealth Bank of Australia

$0.00

(0.00%)

SIEGY

Siemens

$0.00

(0.00%)

T

AT&T

$32.29

0.15 (0.47%)

RDS.A

Royal Dutch Shell

$63.29

0.84 (1.35%)

RHHBY

Roche

$0.00

(0.00%)

NVS

Novartis

$87.49

3.03 (3.59%)

BHP

BHP Group

$52.47

1.18 (2.30%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    May

  • 29

    May

  • 29

    May

  • 31

    May

  • 03

    Jun

  • 03

    Jun

  • 03

    Jun

  • 05

    Jun

  • 08

    Jun

  • 10

    Jun

  • 10

    Jun

  • 11

    Jun

  • 11

    Jun

  • 12

    Jun

  • 20

    Jun

  • 23

    Jun

  • 16

    Jul

  • 24

    Jul

  • 06

    Aug

  • 18

    Aug

  • 19

    Aug

  • 02

    Sep

  • 04

    Nov

GM

General Motors

$35.13

0.01 (0.03%)

, TSLA

Tesla

$190.80

-4.7 (-2.40%)

13:19
05/25/19
05/25
13:19
05/25/19
13:19
Periodicals
Tesla stock in trouble, Barron's says »

Tesla (TSLA) stock is the…

GM

General Motors

$35.13

0.01 (0.03%)

TSLA

Tesla

$190.80

-4.7 (-2.40%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Jun

  • 05

    Jun

  • 11

    Jun

  • 01

    Aug

RNLSY

Renault

$0.00

(0.00%)

13:14
05/25/19
05/25
13:14
05/25/19
13:14
Periodicals
Renault stock may rally, Barron's says »

Shares of French auto…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FMC

FMC Corporation

$70.88

-0.47 (-0.66%)

, DWDP

DowDuPont

$31.10

0.16 (0.52%)

13:11
05/25/19
05/25
13:11
05/25/19
13:11
Periodicals
DowDuPont spinoff a new agriculture stock, FMC safer bet, Barron's says »

The crop-protection and…

FMC

FMC Corporation

$70.88

-0.47 (-0.66%)

DWDP

DowDuPont

$31.10

0.16 (0.52%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

  • 25

    Jun

MGM

MGM Resorts

$25.55

0.19 (0.75%)

13:03
05/25/19
05/25
13:03
05/25/19
13:03
Periodicals
MGM Resorts looks like an attractive gambling play, Barron's says »

MGM Resorts (MGM) stock…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

PYPL

PayPal

$109.82

-0.09 (-0.08%)

, AXP

American Express

$119.52

1.07 (0.90%)

12:30
05/25/19
05/25
12:30
05/25/19
12:30
Periodicals
Big tech failed to dethrone credit cards, Barron's says »

Rather than being cut out…

PYPL

PayPal

$109.82

-0.09 (-0.08%)

AXP

American Express

$119.52

1.07 (0.90%)

MA

MasterCard

$251.40

1.57 (0.63%)

V

Visa

$162.72

1.2 (0.74%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

  • 03

    Jun

  • 05

    Jun

  • 06

    Jun

  • 11

    Jun

  • 25

    Jun

  • 13

    Nov

GOOG

Alphabet

$1,132.99

-7.56 (-0.66%)

, GOOGL

Alphabet Class A

$1,138.90

-5.98 (-0.52%)

07:20
05/25/19
05/25
07:20
05/25/19
07:20
On The Fly
Week in review: How Trump's policies moved stocks »

Catch up on the top…

GOOG

Alphabet

$1,132.99

-7.56 (-0.66%)

GOOGL

Alphabet Class A

$1,138.90

-5.98 (-0.52%)

MSFT

Microsoft

$126.23

0.04 (0.03%)

AMBA

Ambarella

$38.28

1.07 (2.88%)

ON

ON Semiconductor

$17.68

-0.235 (-1.31%)

NKE

Nike

$82.12

-0.51 (-0.62%)

ADDYY

Adidas

$0.00

(0.00%)

UAA

Under Armour

$23.54

0.075 (0.32%)

UA

Under Armour

$20.91

0.08 (0.38%)

FL

Foot Locker

$44.39

-8.455 (-16.00%)

VMC

Vulcan Materials

$126.28

1.25 (1.00%)

FLR

Fluor

$29.04

0.18 (0.62%)

ACM

Aecom

$31.56

-0.03 (-0.09%)

X

U.S. Steel

$13.63

-0.08 (-0.58%)

AKS

AK Steel

$2.00

-0.155 (-7.21%)

NUE

Nucor

$51.12

-0.27 (-0.53%)

DDAIF

Daimler AG

$0.00

(0.00%)

FCAU

Fiat Chrysler

$12.85

0.11 (0.86%)

F

Ford

$9.83

-0.02 (-0.20%)

GM

General Motors

$35.13

0.01 (0.03%)

HMC

Honda

$25.45

0.175 (0.69%)

NSANY

Nissan

$0.00

(0.00%)

TM

Toyota

$118.54

1.16 (0.99%)

VWAGY

Volkswagen

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    May

  • 03

    Jun

  • 03

    Jun

  • 04

    Jun

  • 04

    Jun

  • 05

    Jun

  • 06

    Jun

  • 08

    Jun

  • 10

    Jun

  • 10

    Jun

  • 11

    Jun

  • 12

    Jun

  • 13

    Jun

  • 19

    Jun

  • 19

    Jun

  • 23

    Jun

  • 09

    Jul

  • 24

    Jul

  • 31

    Jul

  • 01

    Aug

  • 06

    Aug

  • 23

    Oct

  • 27

    Oct

UBER

Uber

$41.40

0.94 (2.32%)

17:49
05/24/19
05/24
17:49
05/24/19
17:49
Hot Stocks
Uber board director Ryan Graves intends to resign »

According to a regulatory…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

APTO

Aptose Biosciences

$2.01

0.03 (1.52%)

17:46
05/24/19
05/24
17:46
05/24/19
17:46
Syndicate
Aptose Biosciences files for $40M at-the-market common stock offering »

Piper Jaffray and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Jun

TRNX

Taronis Technologies

$0.48

0.004 (0.84%)

17:26
05/24/19
05/24
17:26
05/24/19
17:26
Syndicate
Breaking Syndicate news story on Taronis Technologies »

Taronis Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

USEG

U.S. Energy

$0.45

0.0373 (9.10%)

17:25
05/24/19
05/24
17:25
05/24/19
17:25
Hot Stocks
U.S. Energy discloses Nasdaq notice regarding delayed 10-Q filing »

U.S. Energy announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$179.03

-0.64 (-0.36%)

17:22
05/24/19
05/24
17:22
05/24/19
17:22
Periodicals
Apple sued over allegedly selling users' iTunes data, Bloomberg says »

Apple is being sued by…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Jun

SPCB

SuperCom

$1.17

-0.005 (-0.43%)

17:21
05/24/19
05/24
17:21
05/24/19
17:21
Hot Stocks
SuperCom discloses Nasdaq notice regarding delayed 20-F filing »

SuperCom received a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

USEG

U.S. Energy

$0.45

0.0373 (9.10%)

17:20
05/24/19
05/24
17:20
05/24/19
17:20
Hot Stocks
U.S. Energy receives noncompliance notice from Nasdaq »

U.S. Energy announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MYOV

Myovant Sciences

$12.39

-0.465 (-3.62%)

17:18
05/24/19
05/24
17:18
05/24/19
17:18
Syndicate
Breaking Syndicate news story on Myovant Sciences »

Myovant Sciences files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MYOV

Myovant Sciences

$12.39

-0.465 (-3.62%)

17:17
05/24/19
05/24
17:17
05/24/19
17:17
Syndicate
Breaking Syndicate news story on Myovant Sciences »

Myovant Sciences files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVS

Novartis

$87.49

3.03 (3.59%)

, QGEN

Qiagen

$38.22

-0.255 (-0.66%)

16:57
05/24/19
05/24
16:57
05/24/19
16:57
Hot Stocks
Qiagen launches diagnostic for PIK3CA biomarkers in breast cancer »

Qiagen (QGEN) announced…

NVS

Novartis

$87.49

3.03 (3.59%)

QGEN

Qiagen

$38.22

-0.255 (-0.66%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    May

  • 31

    May

  • 20

    Jun

  • 06

    Aug

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.